Trade Ideas

Traders Sentiment

Technical Summary



AMS Osram slumps on 'larger than feared' capital increase plan

BUZZ-AMS Osram slumps on 'larger than feared' capital increase plan ** Shares in AMS Osram AMS.S fall 15.9% in Julius Baer premarket trade after the Swiss-listed sensor maker on Wednesday announced plans for a 2.25 bln euro ($2.36 bln) capital increase ** The firm is looking to raise 2.25 bln euros through a rights issue, senior unsecured notes and other financial instruments, covering all expected financing needs until 2025/26 ** "While AMS signaled previously that it tried to avoid a capital i

Julius Baer Signs Partnership Agreement With Swiss To Promote Sustainable Air Travel

BRIEF-Julius Baer Signs Partnership Agreement With Swiss To Promote Sustainable Air Travel Sept 25 (Reuters) - JULIUS BAER GRUPPE AG BAER.S : SIGNS PARTNERSHIP AGREEMENT WITH SWISS TO PROMOTE SUSTAINABLE AIR TRAVEL Further company coverage: BAER.S (Gdansk Newsroom)

Baloise seen down after H1 results miss expectations

BUZZ-Baloise seen down after H1 results miss expectations ** Shares in Baloise Holding BALN.S are seen edging down 1.05% in Julius Baer premarket trade after the Swiss insurer announced first-half results below market expectations ** "Overall a miss versus consensus, driven by the life segment," Vontobel says ** Profit attributable to shareholders

India's Sensex snaps 11-session winning streak; Fed decision eyed

INDIA STOCKS -India's Sensex snaps 11-session winning streak; Fed decision eyed By Archishma Iyer Sept 18 (Reuters) - India's blue-chip stock indexes eased from record highs on Monday, with the Sensex ending a 11-session winning streak, as investors remained cautious ahead of the U.S. Federal Reserve's interest rate decision. The benchmark Nifty 50 .NSEI fell 0.3% to 20,133.3 points, while the S&P BSE Sensex .BSESN slipped 0.4% to 67,596.8 points.

Lonza falls as CEO to leave

BUZZ-Lonza falls as CEO to leave ** Shares in Lonza LONN.S are seen down 5.58% in Julius Baer premarket indications after the Swiss contract drug manufacturer said CEO Pierre-Alain Ruffieux would leave the company at the end of September ** The company says Chairman Albert M. Baehny will become interim CEO until a permanent successor is appointed *


Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.